ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 28

Baseline Serum Inflammatory Biomarkers at Cohort Entry in 1974 Predicted Cardiovascular Disease (CVD) Mortality from 1995 through 2015 in a Prospective, Community-Based Study of Incident Rheumatoid Arthritis (RA) Patients and Matched Non-RA (CN) Subjects

Alfonse T. Masi1, Azeem A. Rehman2, Laura Jorgenson3 and Jean C. Aldag3, 1University of Illinois, College of Medicine at Peoria, Peoria, IL, 2Neurosurgery, University of West Virginia Medical School, Morgantown, WV, 3Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Biomarkers, morbidity and mortality, rheumatoid arthritis (RA) and risk

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Epidemiology and Public Health - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Baseline Serum Inflammatory Biomarkers at Cohort Entry in 1974 Predicted Cardiovascular Disease (CVD) Mortality from 1995 through 2015 in a Prospective, Community-Based Study of Incident Rheumatoid Arthritis (RA) Patients and Matched non-RA (CN) Subjects Author Block: Alfonse T. Masi1, Azeem A. Rehman2, Laura C. Jorgenson1, Jean C. Aldag1, 1University of Illinois College of Medicine at Peoria, Peoria, IL. 2University of West Virginia, Morgantown, WV.

Background/Purpose: Inflammatory pathways have been incriminated in total and cardiovascular disease (CVD) mortality of rheumatoid arthritis (RA) patients (Arthritis Rheum. 2005 Mar;52(3):722-32). Current studies have analyzed serum inflammatory biomarkers in RA patients as related to total and CVD mortality outcomes. No reports are available on serum inflammatory biomarkers before clinical onset of RA as related to total or CVD mortality outcomes. The aim of this study is to investigate baseline pre-clinical inflammatory biomarkers as related to all-cause and CVD mortality of incident RA cases and matched non-RA comparison (CN) subjects in a long-term prospective cohort.

Methods: All incident RA cases were identified who had onsets between 1977 and 1995 from a 1974 community cohort (n=21,061 adults) and satisfied 1987 revised ACR criteria. Cases (n=54) were matched (1 RA: 4CN) with 216 cohort CN subjects on age, gender, and race (Caucasian). All subjects (N=270) were regularly followed for survival through 2015. Two investigators independently determined causes of death (CODs) from the completed death certificate codes without knowledge of RA vs CN status. Baseline (1974) serum immunologic factors were anonymously assayed at national referral laboratories. Assay values were log-transformed and standardized by z-scores in females and males. Multiple imputation (MI) was utilized to enter a minority of randomly missing biomarker z-scores. Individual biomarker z-scores were also analyzed as ranks (1= lowest, 5= highest) within the 54 separate matched sets of 1 RA and 4 CN. Logistic regression was used to identify ranked variables which predicted mortality outcome through 2015, in total deaths and by CVD, respiratory, malignancy, and all other CODs. The dichotomized (neg=0, pos=1) z-scores of predictive ranked factors were entered as covariates in Cox regression models in addition to 1974 baseline demographic and CN_RA status. Pairs of independent dichotomous (neg/pos) selected z-scores were combined (0=both negative, 1=either positive, 2=both positive) to enhance mortality prediction.

Results: In all subjects, total mortality was predicted by ranks of C-reactive protein (CRP) (p=0.033, Exp β 1.17, 95% CIs 1.03-1.33). The CVD deaths were predicted by ranks of soluble tumor necrosis factor receptor 1 (sTNF-R1) (p=0.001 Exp β 1.41, 95% CIs 1.14-1.75) in Cox regression models, including baseline demographic covariates. The dichotomous (neg/pos) z-scores of the preceding predictive biomarkers were paired (CRP_sTNF-R1) into a 3-scale score, which significantly predicted total mortality (p=0.002, Exp β 1.42, 95% CIs 1.13-1.78). That paired predictive biomarker (CRP_sTNF-R1) was an even stronger predictor of CVD mortality (p<0.001, Exp β 2.06, 95% CIs 1.39-3.07) (Figure 1). Its Exp β was slightly greater for RA [2.97 (0.97-9.09)] than CN [1.98 (1.27-3.10)], but was significant (p=0.003) only in the larger sample of CN subjects. Excluding the preceding 50 CVD deaths, the paired biomarker did not predict (p=0.130) total mortality in 220 remaining subjects (Figure 2). In the 220 non-CVD subjects, mortality differed slightly (p=0.045) between those who had neither vs both dichotomous z-scores positive. As found in our previous analyses, RA vs CN status did not predict (p=0.357) 50 CVD deaths [Expβ=1.37 (0.70-2.70)] (Figure 1), but did significantly (p=0.003) predict all other-cause mortality combined in the remaining 220 subjects [Expβ=2.10 (1.29-3.41)] (Figure 2). The paired biomarker was not a significant predictor of the separate non-CVD CODs.

Conclusion: Ranks (1-5) of serum CRP and sTNF-R1 z-scores significantly predicted either total or CVD mortality in 270 subjects. A 3-scale pairing of the preceding dichotomous z-scores (CRP_sTNF-R1) significantly (p<0.001) predicted CVD mortality, but not (p=0.130) non-CVD mortality in the remaining 220 subjects. The relation of pre- and post-clinical onset serum inflammatory biomarkers to total, CVD, and other cause-specific mortality deserves further study in RA and CN subjects.  

 


Disclosure: A. T. Masi, None; A. A. Rehman, None; L. Jorgenson, None; J. C. Aldag, None.

To cite this abstract in AMA style:

Masi AT, Rehman AA, Jorgenson L, Aldag JC. Baseline Serum Inflammatory Biomarkers at Cohort Entry in 1974 Predicted Cardiovascular Disease (CVD) Mortality from 1995 through 2015 in a Prospective, Community-Based Study of Incident Rheumatoid Arthritis (RA) Patients and Matched Non-RA (CN) Subjects [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/baseline-serum-inflammatory-biomarkers-at-cohort-entry-in-1974-predicted-cardiovascular-disease-cvd-mortality-from-1995-through-2015-in-a-prospective-community-based-study-of-incident-rheumato/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/baseline-serum-inflammatory-biomarkers-at-cohort-entry-in-1974-predicted-cardiovascular-disease-cvd-mortality-from-1995-through-2015-in-a-prospective-community-based-study-of-incident-rheumato/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology